Maculopathy: hope from a new therapy

EYLEA® (aflibercept) is the last medication for maculopathy’s cure approved for european use on the 27th November 2012.

The medicine is administered with intravitreal injection and has the advantage to stop VEGF-A and PIGF. The blockage of PIGF (placental growth factor) is an important innovation for the cure of exudative maculopathy.

Moreover, using this drug, the intravitreal injection can be reduced. In USA, EYLEA® was approved even for the treatment of macular edema caused by retina’s central vein’s thrombosis.